rubitecan
Trials 21 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rubitecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006026 ↗ |
| Known as | 9-NC | “The 9-nitrocamptothecin (9-NC) derivative to be used in this study is insoluble in water, but has demonstrated potent antitumor effects in mice and antitumor effect in humans.” NCT00249990 ↗3“Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced Ovarian Cancer” NCT00006230 ↗ “Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme” NCT00005826 ↗ “A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma” NCT00005876 ↗ |
| Known as | 9-Nitro-20 (S)- Camptothecin | “The purposes of this study are: 1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization to patients with metastatic...” NCT00249990 ↗ |
| Known as | 9-Nitro-camptothecin | “Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced Ovarian Cancer” NCT00006230 ↗4“Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme” NCT00005826 ↗ “A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma” NCT00005876 ↗ |
| Known as | L9NC | “The purposes of this study are:
1.1 To determine the efficacy of liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization to patients with metastatic...” NCT00249990 ↗3“Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)” NCT00250068 ↗ “L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin” NCT00250120 ↗ |
| Known as | Liposomal 9-Nitro-20 (S)-Camptothecin | “L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin” NCT00250120 ↗ |
| Known as | nitrocamptothecin | “PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have glioblastoma multiforme.” NCT00005826 ↗1“Arm I: Patients receive nitrocamptothecin orally on days 1-5.” NCT00005871 ↗ |
| Known as | Orathecin | “Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the...” NCT00113256 ↗ |
| Known as | RFS 2000 | “Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced Ovarian Cancer” NCT00006230 ↗3“Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme” NCT00005826 ↗ “A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma” NCT00005876 ↗ “Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction” NCT00113113 ↗ |
| Action | Inhibit | “oral topoisomerase I inhibitor” NCT00006047 ↗ |
| Route | Oral | “Patients receive nitrocamptothecin orally daily on days 1-5.” NCT00005826 ↗ |